MGNX (MacroGenics Corp) Tingkat bathi miturut bathi reged

Simbol resmi perusahaan MacroGenics Inc (MGNX)

Gross profit margin correlates with the implementation of the DART platform for creating bispecific antibodies against tumors. Research continuity is ensured by strict control over the transportation of active components. Rising Margenza sales and clinical trial successes are driving an asset revaluation, while 78.90 determines the latest production efficiency metric for MacroGenics, Inc. (MGNX) on the chart.

MGNX (MacroGenics Corp) riwayat Rentabilitas reged saka 04.07.2022 nganti 20.11.2026

Rincian metrik keuangan lan pasar MacroGenics Inc (MGNX)

- nilai pasar lan prakiraan target analis:
Analisis dhasar perusahaan:MacroGenics
Produk asli MacroGenics

MacroGenics, Inc. maintains high production efficiency protected by Dual-Affinity patents, which enables the minimization of costs when creating complex antibodies. This metric is calculated as the difference between revenue and cost of goods sold, expressed as a percentage, reflecting the business's ability to generate profit before accounting for operating expenses. An analysis of the consolidated gross margin allows for an assessment of the company's resilience to inflation and its competitive advantage over small startups.